Susheel Kumar Yeshala/LinkedIn
Jul 1, 2025, 19:01
Susheel Kumar Yeshala: Attended an Enriching Panel Discussion on Advanced Ovarian Cancer
Susheel Kumar Yeshala, Consultant Medical Oncologist at the American Oncology Institute, shared a post on LinkedIn:
“Attended an enriching panel discussion on advanced ovarian cancer at Raipur recently, alongside some of the most respected voices in oncology.
The session focused on stage III/IV high-grade ovarian cancers, covering critical treatment decisions in the era of PARP inhibitors, HRD testing, HIPEC, and evolving maintenance strategies.
Key takeaways:
– Genetic testing is non-negotiable
– PARP inhibitors have reshaped first-line management for BRCA-mutated and HRD+ patients.
– HIPEC remains controversial, but may have a role in interval cytoreduction (not primary surgery or BRCA+ cases).
– Avoid PARPi in HRD– patients despite label approvals.
– Bevacizumab should be used strategically – more benefit in BRCAwt/HRD+ than in BRCAm.
– Counseling on MDS/AML risks with PARPi is crucial – especially with long-term use.
– Importance of secondary cytoreductive surgery in platinum-sensitive relapse.Grateful to Dr Amish Vora sir and all fellow panelists for sparking deep, practical discussions. As evidence evolves, so must our decision-making.
Special thanks to Dr Ravi Jaiswal for organizing such a wonderful and insightful conference – your efforts made this discussion truly impactful.”
Read more about PARP Inhibitors on Advanced Ovarian Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 18:12
Jul 19, 2025, 17:49
Jul 19, 2025, 17:27
Jul 19, 2025, 17:26
Jul 19, 2025, 16:48
Jul 19, 2025, 16:41